<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The effect of <z:chebi fb="0" ids="9985">vincamine</z:chebi> on initial <z:e sem="disease" ids="C0241832" disease_type="Disease or Syndrome" abbrv="">cerebrovascular insufficiency</z:e> was examined by investigation of data relating to 828 patients from 11 centres </plain></SENT>
<SENT sid="1" pm="."><plain>Most had received 6 tablets/day for 30 days </plain></SENT>
<SENT sid="2" pm="."><plain>The method selected in gathering the data and their processing is described </plain></SENT>
<SENT sid="3" pm="."><plain>Classic symptoms of initial insufficiency were considered after 7, 14, 21 and 30 days and evaluated along with a "seriousness" index relating to the symptomatology as a whole </plain></SENT>
<SENT sid="4" pm="."><plain>The results pointed to continuous improvement in individual symptoms and overall from the outset of treatment, eventually leading to high remission percentages </plain></SENT>
<SENT sid="5" pm="."><plain>Tolerance was generally good and very few cases of side-effects were reported </plain></SENT>
</text></document>